Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02014376 · ClinicalTrials.gov registry record · Phase 2
Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa
A Phase 2 study of Epidermolysis Bullosa, sponsored by Scioderm.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 7
- Study locations
NCT02014376: Completed Phase 2 study of Epidermolysis Bullosa, sponsored by Scioderm.
NCT02014376 is a Phase 2 study of Epidermolysis Bullosa that has completed, run by Scioderm. The registered enrollment target is 48 participants, above the 15-participant average among 10 other Epidermolysis Bullosa trials with a reported enrollment target (220% higher). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02014376, a Phase 2 study of Epidermolysis Bullosa, has completed, sponsored by Scioderm.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study was to assess whether the topical use of SD-101 cream (3% or 6%) was effective in treating wounds in participants with Simplex, Recessive Dystrophic, or Junctional non-Herlitz Epidermolysis Bullosa (EB).
Primary Outcome
The ARANZ SilhouetteStar™, a wound imaging, measurement, and documentation system providing accurate wound assessment, was used to measure the target wound at all visits. Information captured included photographic images, quantitative measures, and other target wound assessment data input to the device by the clinician, all obtained with no contact to the participant's skin. Information about the target wound's measurement history was available on this system so that the serial progression of th
Conditions Studied
Interventions
- DRUG SD-101 dermal cream (3%)
- DRUG SD-101 Dermal Cream (6%)
- DRUG Vehicle (SD-101 0%)
Study Locations (7)
California
- - Palo Alto
Illinois
- - Chicago
Missouri
- - St Louis
New Jersey
- - Hackensack
North Carolina
- - Chapel Hill
Texas
- - San Antonio
Washington
- - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2014-01-06 |
| Est. Completion | 2014-06-24 |
| Phase | Phase 2 |
What the finished NCT02014376 record still lists
NCT02014376 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, above the 15-participant average among 10 other Epidermolysis Bullosa trials with a reported enrollment target (220% higher).
The record links to 1 condition, with Epidermolysis Bullosa appearing as the primary indexed condition, and to 3 interventions - of which SD-101 dermal cream (3%) is the first listed.
NCT02014376 lists 7 locations in 7 states (California, Illinois, Missouri).
Frequently Asked Questions
What is clinical trial NCT02014376 about?
NCT02014376 is a clinical study titled "Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa". The purpose of this study was to assess whether the topical use of SD-101 cream (3% or 6%) was effective in treating wounds in participants with Simplex, Recessive Dystrophic, or Junctional non-Herlitz Epidermolysis Bullosa (EB).
What is the current status of trial NCT02014376?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2014-01-06. Estimated completion is 2014-06-24.
What conditions does trial NCT02014376 study?
This clinical trial studies the following conditions: Epidermolysis Bullosa.
What interventions are being tested in trial NCT02014376?
The interventions under investigation include: SD-101 dermal cream (3%) (DRUG), SD-101 Dermal Cream (6%) (DRUG), Vehicle (SD-101 0%) (DRUG).
Who is sponsoring clinical trial NCT02014376?
This trial is sponsored by Scioderm, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02014376 being conducted?
This trial has 7 study locations across California, Illinois, Missouri, New Jersey, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epidermolysis Bullosa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02014376's enrollment target sits among peer trials
48 1st of 10 higher than 10 of 10 other Epidermolysis Bullosa trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Epidermolysis Bullosa trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients
COMPLETED · Phase 2
-
Study of Alwextin® Cream in Treating Epidermolysis Bullosa
COMPLETED · Phase 2
-
A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis Bullosa
COMPLETED · Phase 2
-
Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa
RECRUITING · Phase 1
-
A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients
ACTIVE NOT RECRUITING · Phase 3
-
Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III)
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI